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Editor’s key points
† Changes in energy
metabolism in response
to sevoflurane, propofol,
or Intralipid were
measured in working rat
hearts after ischaemia
and reperfusion.
† Sevoflurane, but not
propofol, improved the
recovery of heart function
and decreased calcium
overload via enhanced
glucose uptake.
† This study begins to
explain the mechanisms
behind the
cardioprotective effects
of sevoflurane.
Background. So far, no study has explored the effects of sevoflurane, propofol, and
Intralipid on metabolic flux rates of fatty acid oxidation (FOX) and glucose oxidation
(GOX) in hearts exposed to ischaemia–reperfusion.
Methods. Isolated paced working rat hearts were exposed to 20 min of ischaemia and 30
min of reperfusion. Peri-ischaemic sevoflurane (2 vol%) and propofol (100 mM) in the
formulation of 1% Diprivanw were assessed for their effects on oxidative energy
metabolism and intracellular diastolic and systolic Ca2+ concentrations. Substrate flux
was measured using [3H]palmitate and [14C]glucose and [Ca2+] using indo-1AM. Western
blotting was used to determine the expression of the sarcolemmal glucose transporter
GLUT4 in lipid rafts. Biochemical analyses of nucleotides, ceramides, and 32
acylcarnitines were also performed.
Results. Sevoflurane, but not propofol, improved the recovery of left ventricular work
(P¼0.008) and myocardial efficiency (P¼0.008) compared with untreated ischaemic
hearts. This functional improvement was accompanied by reduced increases in post-
ischaemic diastolic and systolic intracellular Ca2+ concentrations (P¼0.008). Sevoflurane,
but not propofol, increased GOX (P¼0.009) and decreased FOX (P¼0.019) in hearts
exposed to ischaemia–reperfusion. GLUT4 expression was markedly increased in lipid
rafts of sevoflurane-treated hearts (P¼0.016). Increased GOX closely correlated with
reduced Ca2+ overload. Intralipid alone decreased energy charge and increased long-
chain and hydroxyacylcarnitine tissue levels, whereas sevoflurane decreased toxic
ceramide formation.
Conclusions. Enhanced glucose uptake via GLUT4 fuels recovery from Ca2+ overload after
ischaemia–reperfusion in sevoflurane- but not propofol-treated hearts. The use of a high
propofol concentration (100 mM) did not result in similar protection.
Keywords: anaesthetics inhalation, sevoflurane; anaesthetics i.v., propofol; energy
metabolism; myocardial reperfusion injury; rats
Accepted for publication: 28 January 2011
Cardiac metabolism critically affects contractile function in
acute and chronic disease states.1 Pronounced metabolic
shifts in substrate preference, namely between glucose oxi-
dation (GOX) and fatty acid oxidation (FOX), occur in
obesity and diabetes, heart failure, and ischaemia–reperfusion
injury. From multiple previous metabolic studies of the heart,
the prevailing concept suggested that favouring economic
(i.e. ATP-sparing) glucose over FOX is especially beneficial in
stressed hearts with limited oxygen supply.2 Using the
aerobically perfused working rat heart model, we recently
showed in an extensive metabolic analysis that sevoflurane,
propofol, and its solvent Intralipid elicit distinct metabolic
profiles in the myocardium,3 which may have important
implications for the already jeopardized diseased heart. In
that and previous studies, we demonstrated that sevoflurane
reduces FOX by redistributing the principal fatty acid trans-
porter CD36 from lipid rafts to non-functional intracellular
pools (short-term effects)3 and by decreasing peroxisome
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proliferator-activated receptor-regulated gene products
involved in FOX (long-term effects).4 In contrast, propofol
(100 mM) increases GOX by dephosphorylating the pyruvate
dehydrogenase (PDH) complex, elevates formation of lipo-
toxic ceramides, and inhibits 3-hydroxy-acyl-coenzyme A
(CoA) dehydrogenase, a critical enzyme of mitochondrial
b-oxidation.3 So far, however, no study has directly measured
the metabolic effects of sevoflurane and propofol on flux
rates of glucose and fatty acids in hearts subjected to ischae-
mia–reperfusion injury. On the basis of our previous results,
we hypothesized that the two anaesthetics for which cardio-
protective properties were reported in the past5 – 8 would dif-
ferentially modulate cardiac metabolism under ischaemia–
reperfusion conditions and that changes in metabolism
could be related to measured intracellular Ca2+ overload.
Beat-to-beat Ca2+ recordings and contractility in the
working rat heart model served as outcome measures and
were related to changes in energy metabolism and
metabolites.
Methods
Working heart perfusion protocols and beat-to-beat
intracellular Ca21 measurements
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996)
and the experimental protocol used in this investigation
was approved by the University of Alberta Animal Policy
and Welfare Committee. Male Sprague–Dawley rats (350–
400 g), treated according to the guidelines of the University
of Alberta Animal Policy and Welfare Committee and the
Canadian Council on Animal Care, were killed with an over-
dose of pentobarbital (150 mg kg21, i.p.). Each heart was
rapidly removed and perfused initially (15 min) in a non-
working Langendorff mode with the Krebs–Henseleit sol-
ution. Working mode perfusion was subsequently established
(11.5 mm Hg preload, 80 mm Hg afterload, 5 Hz) with a recir-
culating perfusate (100 ml, 378C, pH 7.4, gassed with 95%
O2/5% CO2) that consisted of a modified Krebs–Henseleit sol-
ution containing (mM): KCl (4.7), NaCl (118), KH2PO4 (1.2),
MgSO4 (1.2), CaCl2 (2.5), NaHCO3 (25), glucose (11), palmitate
(1.2, pre-bound to 3% bovine serum albumin), and insulin
100 mU litre21. To determine beat-to-beat intracellular
Ca2+ concentrations, hearts were loaded with the fluorescent
[Ca2+] indicator indo-1AM (5 mM, 25 min) in the working
mode perfusion. After a washout period of 5 min in the Lan-
gendorff mode, the working mode was re-established with a
fresh modified Krebs–Henseleit solution using a second per-
fusion circuit. With the aid of a random table, hearts were
assigned to the four treatment groups (Supplementary Fig.
S1) (n¼6 for each group): (i) time-matched perfusion
without treatment (IR), (ii) sevoflurane8 (SEVO+IR) adminis-
tered at 2 vol%, (iii) propofol 100 mM (PROP100+IR) in the
formulation of Diprivanw 1% (AstraZeneca Inc., Mississauga,
Ontario, Canada), or (iv) the corresponding Intralipid
control (INTRA100+IR). A concentration of 100 mM was
chosen for propofol since previous studies showed a clear
dose–response for its cytoprotection, with 100 mM having
the most pronounced protection in hearts.6 All hearts were
subjected to 20 min of 378C zero-flow ischaemia and 30
min of reperfusion and then immediately frozen in liquid
nitrogen and stored at 2808C for subsequent analyses.
Indo-1 fluorescence was measured from a small area
(0.3 cm2) of the epicardial surface of the left ventricle
using a spectrofluorometer (Photon Technology Inter-
national, London, Ontario, Canada). Signals were acquired
at 500 Hz, and the ratio of indo-1 fluorescence emitted at
405 and 485 nm (F405/F485 ratio) was calculated to provide
an index of intracellular [Ca2+].9 Cardiac output (ml min21)
and aortic flow (ml min21) were measured using ultrasonic
flow probes (Transonic T206, Transonic Systems Inc., Ithaca,
NY, USA). Left ventricular work (LVW; ml min21 mm Hg), cor-
onary flow (ml min21), and coronary vascular conductance
(ml min21 mm Hg21) were calculated as described pre-
viously.9 Measurements of mechanical functions were aver-
aged for the pre- and post-ischaemic period. Myocardial
efficiency was defined as the ratio of LVW per produced
acetyl-CoA per gram dry weight (dry wt).
Metabolic flux measurements: determination of GOX
and FOX
Rates (expressed as mmol g21 dry wt min21) of GOX and FOX
were measured by determining 14CO2 production and
3H2O
production in hearts perfused with [U-14C]glucose and
[9,10-3H]palmitate, respectively.10 Samples were obtained
every 10 min and rates were calculated for each time interval
and were averaged for the pre- and post-ischaemic period.
Subsequently, the difference between averaged preischae-
mic and averaged post-ischaemic values was computed.
Determination of nucleotides and ceramides
Adenine nucleotides and ceramides were measured after
tissue extraction using high-performance liquid chromatog-
raphy, as described previously.3 The energy charge of the
adenylate pool was computed as (ATP+0.5 ADP)/
(ATP+ADP+AMP).
Mass spectrometry for acylcarnitine profiling
From four randomly chosen hearts of each group, tissue
levels of 32 acylcarnitine species were measured using elec-
trospray ionization tandem mass spectrometry.3 Acylcarni-
tines were extracted from heart tissue with methanol and
quantified using eight isotopically labelled internal standards
(Cambridge Isotopes Laboratories, Andover, MA, USA). Pre-
cursor ions of m/z 85 in the mass range of m/z 150–450
were acquired on a PE SCIEX API 365 LC-ESI-MS/MS instru-
ment (Applied Biosystems, Foster City, CA, USA).
Determination of tissue triglyceride content and
[9,10-3H]palmitate incorporation
After chloroform/methanol extraction of lipids from cardiac
tissue, triglyceride content was quantified colorimetrically
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with the enzymatic assay kit L-Type Triglyceride M (Wako
Pure Chemical Industries, Richmond, VA, USA). Incorporation
of [9,10-3H]palmitate into triglycerides was counted.3
Determination of tissue glycogen content and
[U-14C]glucose incorporation
Glycogen content (mmol glucosyl units g21 dry wt) was deter-
mined by powdering heart tissue samples and subjecting
them to alkaline extraction with 30% KOH followed by
ethanol precipitation and acid hydrolysis (2 N H2SO4) and
analysis of glucose content. Incorporation of [U-14C]glucose
into glycogen was counted.3
PDH complex activity assay
PDH activity was measured by the radioisotopic-coupled
enzyme assay which determines the ratio of PDHactive/
PDHtotal.
11
Immunoblotting for GLUT4 expression in lipid rafts
and phosphorylated AMP-activated protein kinase/
AMP-activated protein kinase ratio
Whole tissue extracts and detergent-free fractions 2 and 3 of
lipid rafts/caveolae containing GLUT4 were prepared from the
five IR and five SEVO+IR hearts from which complete Ca2+
and metabolic data were obtained, and western blotting
was performed as described previously.3 The phosphorylated
AMP-activated protein kinase (AMPK)/AMPK ratio was deter-
mined in four randomly chosen hearts. The following
primary antibodies were used: rabbit anti-GLUT4 (Cell Signal-
ing Technology, Danvers, MA, USA), mouse anti-flotillin
(610820, BD Biosciences, Mississauga, Ontario, Canada),
rabbit anti-AMPK (2532, Cell Signaling Technology), rabbit
anti-pY172-AMPK (2531, Cell Signaling Technology), and
rabbit anti-a-actin (I-19, Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Protein band intensities were quantified
by ImageJ software [http://rsbweb.nih.gov/ij/ (accessed
December 1, 2008)].
Statistical analysis
The sample size was calculated based on previously reported
data for the recovery of left ventricular function and changes
in GOX and diastolic Ca2+ concentrations.9 With an expected
difference of 50% between group means, 20% SD of the
means, the significance level a¼0.05/3 (Bonferroni’s correc-
tion for three groups since PROP100+IR was compared
with IR and INTRA100+IR), and b¼0.8, a sample size of
five hearts per group was necessary. The significance of
differences in haemodynamic and metabolic variables
among groups was determined by Student’s t-test (two
groups) or by analysis-of-variance (ANOVA) followed by the
Student–Newman–Keuls method for post hoc analysis
(three groups) or by non-parametric methods (Wilcoxon–
Mann–Whitney rank-sum test and Kruskal–Wallis
analysis-of-variance on ranks) depending on the underlying
data distribution. To test the association between GOX and
changes in intracellular Ca2+ concentrations, linear
regression analysis was performed. The correlation coeffi-
cient R, the standard error of the estimate, and the corre-
sponding P-value are reported. Differences are considered
significant if P,0.05. SigmaStat (version 3.5; Systat Software,
Inc., Chicago, IL, USA) was used for the analyses.
Results
Sevoflurane but not propofol reduces Ca21 overload
and increases myocardial efficiency after ischaemia–
reperfusion injury in working hearts
During baseline aerobic perfusion, LVW was stable and
similar among groups. Upon initiation of global no-flow
ischaemia, all detectable left ventricular mechanical function
ceased virtually immediately (,60 s). After 20 min of zero-flow
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Fig 1 Changes in LVW (DLVW, A) and myocardial efficiency (DME,
B). IR, hearts exposed to ischaemia–reperfusion; SEVO+IR,
hearts exposed to ischaemia–reperfusion and treated with 2
vol% sevoflurane before and after ischaemia; PROP100+IR,
hearts exposed to ischaemia–reperfusion and treated with 100
mM propofol before and after ischaemia; INTRA100+IR, the cor-
responding Intralipid control group. Complete haemodynamic
data were obtained for six hearts in each group except for IR
and INTRA100+IR with only five hearts (also see Supplementary
Table S1). Complete metabolic data were obtained in six hearts of
each group except for IR and SEVO+IR with five hearts and
INTRA+IR with four hearts. P-values were computed using non-
parametric tests.
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ischaemia and 30 min of reperfusion, the decrease in LVW
(P¼0.008), peak systolic pressure (P¼0.035), and stroke
volume (P¼0.016) was significantly smaller in sevoflurane-
treated hearts when compared with untreated control hearts
(Fig. 1A; Supplementary Table S1). In contrast, propofol was
not protective when compared with untreated control hearts
or Intralipid (P¼0.41). Myocardial efficiency was higher in
sevoflurane-treated hearts (P¼0.008), but was depressed to a
similar extent in propofol-treated and untreated hearts
(P¼0.64; Fig. 1B). During global no-flow ischaemia, Ca2+ transi-
ents ceased within 5 min and the average intracellular Ca2+
concentrations (termed diastolic Ca2+), an index of ATP
depletion and ischaemic contracture and injury, were lowest
in sevoflurane-treated hearts (P¼0.008) but were unchanged
in propofol- or Intralipid-treated hearts (P¼0.56; Fig. 2A). Dia-
stolic (P¼0.008; Fig. 2B) and systolic Ca2+ concentrations
(P¼0.008; Fig. 2C) measured during reperfusion were decreased
in sevoflurane-treated hearts when compared with untreated
control hearts. In contrast, propofol did not significantly
decrease Ca2+ overload during reperfusion (Ddiastolic Ca2+,
P¼0.09;Dsystolic Ca2+,P¼0.09; Fig. 2; Supplementary Table S2).
Sevoflurane but not propofol increases GOX after
ischaemia–reperfusion injury in working hearts
Determinations of GOX, FOX, and Krebs cycle acetyl-CoA
production rates after ischaemia–reperfusion injury
revealed an increase in GOX in sevoflurane-treated hearts
when compared with untreated control hearts (P¼0.009)
(Fig. 3A; Supplementary Table S3). In accordance with our
previous report, sevoflurane-treated hearts also showed a
significant decrease in FOX (P¼0.016; Fig. 3B) and a corre-
sponding decline in acetyl-CoA production (P¼0.03;
Fig. 3C). Lower peak ischaemic Ca2+ concentrations
(P¼0.002) and changes in diastolic (P¼0.002) and systolic
(P¼0.005) Ca2+ concentrations were closely correlated
with higher GOX (Fig. 4). No changes in GOX (P¼0.45),
FOX rate (P¼0.43), or acetyl-CoA turnover (P¼0.45) were
observed in propofol- and Intralipid-treated hearts during
reperfusion (Fig. 3; Supplementary Table S3). Levels of tri-
glycerides were markedly reduced in sevoflurane-
(P¼0.044) but not propofol-treated hearts (P¼0.51; Sup-
plementary Table S4), suggesting reduced fatty acid
uptake, as previously shown.3
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Fig 2 Intracellular Ca2+ concentrations at the end of ischaemia (A) and at the end of reperfusion (diastolic, B; systolic, C; and transient ampli-
tude, D) in untreated hearts (IR, n¼5) or in hearts that were exposed to sevoflurane (2 vol%, SEVO+IR, n¼6), propofol (100 mM, PROP100+IR,
n¼6), or Intralipid (INTRA100+IR, n¼5). P-values were computed using non-parametric tests.
Ca2+ overload, metabolism, and anaesthetics BJA
795
Sevoflurane increases GLUT4 expression in lipid rafts
in an AMPK-independent manner after ischaemia–
reperfusion injury in working hearts
To further explore the mechanism of the sevoflurane-induced
increase in GOX, the expression of functional, that is, lipid
raft-associated GLUT4 was determined in working hearts
exposed to ischaemia–reperfusion. Sevoflurane-treated
hearts exhibited higher GLUT4 expression in lipid rafts
when compared with untreated control hearts (P¼0.019;
Fig. 5A), which was not related to increased activity of
AMPK (P¼0.72; Fig. 5B). Also, sevoflurane did not change
the activity of the PDH complex (PDC; P¼0.22; Fig. 5C). Total
glycogen content and radioactively labelled glycogen were
not different among groups (Supplementary Table S4). Peri-
ischaemic administration of sevoflurane (P¼0.009) but not
propofol (P¼0.28) markedly reduced ceramide formation
(Supplementary Fig. S2). Intralipid administration increased
long-chain acylcarnitines (P≤0.023) and hydroxyacylcarni-
tines (P¼0.027; Supplementary Tables S5 and S6) and mark-
edly reduced the cardiac energy charge (P¼0.012;
Supplementary Table S7).
Discussion
In this study, we used the working rat heart model, which
allows the measurement of metabolic flux rates under care-
fully controlled conditions of energy substrate supply and
physiological workload. Under aerobic conditions, more
than 70% of cardiac energy requirements is provided by
fatty acids1 12 with the remainder coming from glucose
and to a much lesser degree from lactate/pyruvate or
amino acids. The inclusion of palmitate in the perfusate is
an important aspect of this study as it permits assessment
of myocardial substrate preference, a key determinant of
the ability of cardiac muscle to recover after ischaemia.
During ischaemia–reperfusion, metabolic flexibility (i.e.
switching from one to the alternative substrate) is virtually
lost whereby the more rapid recovery of FOX inhibits the
rates of GOX.13 14 The results of our study now provide evi-
dence that sevoflurane, in contrast to propofol, reduces
FOX and concomitantly increases GOX during reperfusion.
These notions extend our recent findings from aerobically
perfused working hearts, where we demonstrated that sevo-
flurane reduces FOX by decreasing fatty acid uptake at the
sarcolemma and increases net GOX.3 There is ample evi-
dence of a close and causal relationship between cardiac
metabolism and contractility, mainly from clinical studies in
patients with inherited deficiencies of metabolic enzymes15
and more recently from studies with genetically modified
mice.16 Moreover, effects of metabolic interventions on
mechanical function support the concept that energy
metabolism indeed is a critical factor in the haemodynamic
deterioration of the failing heart. Overexpression of GLUT1,
the glucose transporter responsible for basal
insulin-independent cellular glucose uptake, delays pro-
gression to failure after aortic constriction in murine
hearts.16 On the other hand, inhibition of FOX via sarcolem-
mal (CD36)17 or mitochondrial (CPT1) fatty acid uptake18 or
at the level of b-oxidation19 may improve mechanical work
in the stressed heart. Stimulation of GOX directly or indirectly
(i.e. by inhibition of FOX)1 has reportedly salutary economic
effects on cardiac metabolism. First, the oxygen cost of
fatty acid as substrate is 11% higher compared with
glucose since FOX shifts a greater proportion of electrons to
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ubiquinone complex II of the respiratory chain.20 Also, four-
carbon units as derived from glucose metabolism increase
the concentrations of citric acid cycle intermediates allowing
more efficient oxidation of two-carbon units. Secondly, FOX
couples less efficiently electron with proton flux (‘uncou-
pling’) in mitochondria, thereby increasing the formation of
reactive oxygen species.21 Thirdly, increased FOX uncouples
glycolysis from GOX and enhances H+ formation.22 We have
previously reported on the physiological importance of
sevoflurane-mediated fuel shifts in patients undergoing
off-pump coronary artery bypass graft surgery.4 In that
study, sevoflurane-induced attenuation of transcripts
involved in FOX closely correlated with improved cardiac con-
tractility. The results of the present study extend our previous
findings and reveal that the long-term transcriptional meta-
bolic remodelling by sevoflurane is indeed a true mirror of its
short-term metabolic phenotype.
In the current study, sevoflurane-mediated increase in
GOX is likely to be the result of increased GLUT4 expression
in lipid rafts, since the activity of the master switch enzyme
of GOX, the PDC, was unaffected by sevoflurane. GLUT4 is
the insulin-sensitive glucose transporter of the heart, which
is translocated from intracellular compartments, mainly
endosomes, to sarcolemmal caveolae,23 in response to
increased cardiac contractility, insulin stimulation, or acti-
vation of AMPK due to metabolic stress.24 25 Our results
show that the increased GLUT4 expression in sevoflurane-
treated hearts is independent of AMPK activation, but since
GLUT4 translocation is contractility-dependent, the increased
GLUT4 expression in sevoflurane-treated hearts could be a
consequence of the improved contractility rather than a
cause. However, the ability of sevoflurane in aerobically per-
fused hearts to relatively increase net GOX by decreasing
FOX, while maintaining GLUT4 expression in lipid rafts at a
lower contractility (negative inotropy), rather implies that
enhanced glucose uptake and oxidation may be at least
partly contributing to the improved functional recovery in
sevoflurane-treated hearts. Inhibition of fatty acid uptake
and oxidation are known to increase GLUT4 expression via
the glucose–fatty acid cycle (‘Randle cycle’).1 26 Moreover,
long-chain CoAs and triglycerides may activate several
serine kinases that inhibit insulin action.27 In our study, sevo-
flurane also decreased the formation of ceramides, which are
known to mediate insulin resistance by inhibiting protein
kinase B.28 Inhibition of serine palmitoyltransferase, the rate-
limiting enzyme in ceramide synthesis, reduces FOX but con-
comitantly increases GOX.29 During ischaemia–reperfusion,
ceramides also accumulate in lipid rafts,30 which might
affect GLUT4 function. Using microdialysis probes, Carles
and colleagues31 showed a better availability of glucose in
the skeletal muscle of patients during ischaemia and reper-
fusion after sevoflurane exposure. This is in line with obser-
vations from skeletal muscle cells, showing that
sevoflurane enhances glucose uptake through activation of
tyrosine kinases.32 Collectively, sevoflurane potentially
improves insulin signalling in the heart. In our study, sevo-
flurane also markedly reduced the accumulation of triglycer-
ides and ceramides in the post-ischaemic heart. Beside their
insulin-antagonistic effects, ceramides promote inflam-
mation, increase mitochondrial Ca2+, and impair mitochon-
drial respiration.33 34 On the other hand, long-chain and
hydroxyacylcarnitines, typical markers of a dysfunctional
fatty acid metabolism,35 accumulated in Intralipid-treated
hearts. Acylcarnitines are increased in ischaemic hearts
due to inhibition of b-oxidation and may worsen intracellular
Ca2+ overload.36 Amphiphilic acylcarnitines are further
capable of inhibiting mitochondrial ATP-dependent potass-
ium channels37 and ‘acylate’ essential metabolic enzymes.
Hence, it is not surprising that we observed a significant
decrease in energy charge in Intralipid-treated hearts.
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Reduced mitochondrial respiration as evidenced by lower
acetyl-CoA turnover in sevoflurane-treated hearts resembles
a state of ‘metabolic hibernation’, previously identified as a
typical feature of the preconditioned protected state of the
heart.38 Volatile anaesthetics such as sevoflurane activate
ATP-dependent potassium channels, a key player in the pre-
conditioning process,8 which is tightly regulated by inter-
mediary metabolism. In this regard, it is interesting to note
that sevoflurane did not alter cardiac glycogen stores,
despite the well-known activation of glycogen synthase
kinase-3b by volatile anaesthetics.39 However, the glycogen-
salvaging effects by sevoflurane may be only seen after more
extended ischaemic periods. Although previous work
suggests that brief sevoflurane preconditioning increases
phosphorylation of AMPK during reperfusion,40 in our proto-
cols where sevoflurane was administered during the entire
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Fig 5 GLUT4 expression, AMPK, and PDH activities in untreated hearts (IR) or in hearts exposed to sevoflurane (2 vol%, IR+SEVO). (A) Repre-
sentative western blots (n¼5 per group) of GLUT4 expression in lipid rafts and quantification to flotillin. (B) Representative western blots of
AMPK and activity estimated from the ratio of pAMPK and total AMPK. a-Actin was used as a loading control (n¼4 for each group). (C) PDH
activity calculated as active over total PDH (n¼5 for each group). P-values were computed using Student’s t-test or the Wilcoxon–
Mann–Whitney test (WMW).
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experimental protocol, no increase in AMPK phosphorylation
was observed. Nonetheless, our data lend further support to
the concept of a tight interplay among energy metabolism,
preconditioning, and cardioprotection.
Our study has several limitations. In our analyses, we
focused on the intrinsic metabolic effects of the two anaes-
thetics and Intralipid. Hence, we compared sevoflurane-
treated hearts with untreated control hearts, and since
Intralipid-treated hearts also exhibited some changes in
metabolites, propofol-treated hearts were compared with
both untreated and Intralipid-treated hearts as described
previously.3 A direct comparison between sevoflurane- and
propofol-treated hearts would not have allowed delineating
the specific metabolic effects of these pharmacological
agents and linking them to cardiac function and Ca2+ over-
load. Although we did not observe significant cardioprotec-
tion in propofol-treated hearts in our experiments, we
cannot exclude some protection with 100 mM propofol or
other concentrations in other experimental settings. In
fact, propofol is known to have Ca2+ channel-blocking activi-
ties and baseline and changes in diastolic Ca2+ concen-
trations tended to be lower in the propofol group (Fig. 2;
Supplementary Table S2). However, ischaemic Ca2+ concen-
trations and changes in systolic Ca2+ concentrations were
not different from untreated hearts. Irrespectively, the
failure of propofol to improve post-ischaemic cardiac func-
tion is unlikely to be due to its negative inotropic effects
since propofol (100 mM) did not suppress cardiac contractility
under aerobic conditions. Rather the increased Ca2+ overload
in propofol-treated hearts suggests the ischaemic damage
as cause for the poor recovery. Finally, since the effects of
propofol on rat myocardium may be different from those
on human myocardium, we should be careful in extending
the current results to human hearts.
In conclusion, this study demonstrates that enhanced
glucose uptake via GLUT4 fuels fast recovery from Ca2+ over-
load after ischaemia–reperfusion injury in sevoflurane-
treated hearts. Our current experimental results confirm pre-
vious clinical findings4 5 41 in a well-controlled physiological
model and shed new light on the potentially cardioprotective
metabolic effects of sevoflurane.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
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